Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
- Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
- Offering more effective personalized screening solutions supports Exact Sciences’ commitment to help detect cancer earlier.”
For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients. - Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes.
- The test is processed in Marshfield, WI at PreventionGenetics, an Exact Sciences laboratory qualified to perform high-complexity clinical laboratory testing that has been providing quality genetic testing since 2004 and joined Exact Sciences in 2022.